title: Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.
abstract: This review analyses a recent advance in diabetes pharmacotherapeutics: the combination of insulin and glucagon-like peptide 1 receptor agonists (GLP 1 RA). It describes the rationale for such a combination, and discusses the impact of such therapy on glycaemic control. The paper also assesses other benefits of the combination, and provides a practical framework for pragmatic, rational use of this treatment.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D052216:Glucagon-Like Peptide 1